Live feed07:05:00·9mPRReleasevia QuantisnowZenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026ByQuantisnow·Wall Street's wire, on your screen.ZBIO· Zenas BioPharma Inc.Health Care